
News|Articles|December 10, 2015
How the Type of Antiplatelet Agents Can Impact Patient Outcomes
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.
Advertisement
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma
2
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
3
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
4
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
5




















































































































